80,841 Shares in Avantor, Inc. $AVTR Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new stake in Avantor, Inc. (NYSE:AVTR) in the 2nd quarter, HoldingsChannel.com reports. The firm bought 80,841 shares of the company’s stock, valued at approximately $800,000.

A number of other hedge funds have also recently added to or reduced their stakes in AVTR. Royal Bank of Canada grew its position in shares of Avantor by 104.3% during the first quarter. Royal Bank of Canada now owns 203,738 shares of the company’s stock worth $3,302,000 after acquiring an additional 104,022 shares during the last quarter. Empowered Funds LLC raised its holdings in Avantor by 40.3% during the first quarter. Empowered Funds LLC now owns 17,659 shares of the company’s stock worth $286,000 after purchasing an additional 5,075 shares in the last quarter. Cetera Investment Advisers lifted its position in Avantor by 40.2% in the second quarter. Cetera Investment Advisers now owns 40,289 shares of the company’s stock valued at $542,000 after purchasing an additional 11,543 shares during the period. Quantbot Technologies LP acquired a new stake in Avantor in the second quarter valued at about $232,000. Finally, Arrowstreet Capital Limited Partnership increased its position in Avantor by 214.9% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 124,076 shares of the company’s stock worth $1,670,000 after purchasing an additional 84,679 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Ratings Changes

AVTR has been the topic of a number of recent analyst reports. Royal Bank Of Canada upped their price objective on Avantor from $9.00 to $14.00 and gave the stock a “sector perform” rating in a report on Thursday, July 30th. Evercore set a $10.50 target price on shares of Avantor in a research report on Monday, July 6th. Jefferies Financial Group raised Avantor from an “underperform” rating to a “hold” rating and set a $13.00 price objective for the company in a research note on Wednesday, July 29th. Sanford C. Bernstein began coverage on Avantor in a research report on Friday, June 26th. They issued a “market perform” rating and a $10.50 price target for the company. Finally, TD Cowen restated a “hold” rating on shares of Avantor in a research report on Wednesday, July 15th. Two analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Avantor currently has a consensus rating of “Hold” and an average price target of $12.00.

Avantor Price Performance

Shares of NYSE:AVTR opened at $13.36 on Wednesday. The company has a market cap of $9.04 billion, a P/E ratio of -15.91, a P/E/G ratio of 10.29 and a beta of 0.89. The company has a quick ratio of 1.18, a current ratio of 1.78 and a debt-to-equity ratio of 0.65. Avantor, Inc. has a 52 week low of $7.26 and a 52 week high of $15.93. The business has a fifty day simple moving average of $11.35 and a 200-day simple moving average of $9.57.

Avantor (NYSE:AVTR) last issued its quarterly earnings results on Wednesday, July 29th. The company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.19 by $0.02. Avantor had a negative net margin of 8.81% and a positive return on equity of 9.92%. The firm had revenue of $1.69 billion during the quarter, compared to analyst estimates of $1.61 billion. During the same quarter in the prior year, the business posted $0.24 earnings per share. Avantor’s revenue for the quarter was up .5% compared to the same quarter last year. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. Equities research analysts forecast that Avantor, Inc. will post 0.81 EPS for the current year.

Avantor Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.